




RECEIVED
JUL 24 2001 #3
TECH CENTER 1600/2900
ATTORNEY DOCKET NO. 50025/003002

Certificate of Mailing: Date of Deposit: July 16, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Barry
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Victor J. Dzau <i>et al.</i>	Art Unit:	1632
Serial No.:	09/839,752	Examiner:	Not Yet Assigned
Filed:	April 19, 2001	Customer No.:	21559
Title:	Therapeutic Use of Cis-Element Decoys <i>In Vivo</i>		

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached Form PTO-1449.

Submission of this Statement is not a representation that a search has been made, nor is the inclusion of information in this Statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 08/524,206, filed on September 8, 1995. The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application:

5,683,985 11/04/97 Chu et al.

5,631,237 05/20/97 Dzau et al.

Barinaga et al., "Gene Therapy for Clogged Arteries Passes Test in Pigs," *Science* 265:738 (1994).

Bielinska et al., "Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides," *Science* 250:997-999 (1990).

Chien, "Molecular Advances in Cardiovascular Biology," *Science* 260:916-917 (1993).

Dalton, "Cell Cycle Regulation of the Human *cdc2* Gene," *The EMBO Journal* 11(5):1979-1804 (1992).

Ebbecke et al., *European Heart Journal* (Suppl.) 12:11 (1991).

Hiebert et al., "E1A-dependent Trans-activation of the Human Myc Promoter Is Mediated by the E2f Factor," *Proc. Natl. Acad. Sci. U. S. A.* 86:3594-3598 (1989).

Hug et al., "Liposomes for the Transformation of Eukaryotic Cells," *Biochem. Biophys. Acta* 1097:1-17 (1991).

Hutchinson et al., *Circulation* (Suppl. I) 86:I-226 (1992).

Kaneda et al., "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver," *Science* 243:375-378 (1989).

Libby et al., "A Cascade Model for Restenosis. A Special Case of Atherosclerosis Progression," *Circulation* 86:III-47 - III-52 (1992).

Mannino et al., "Liposome Mediated Gene Transfer," *BioTechniques* 6:682-690 (1988).

Milligan et al., "Current Concepts in Antisense Drug Design," *J. Med. Chem.* 36:1923-37 (1993).

Morishita et al., "In Vivo Gene Transfer into Intact Blood Vessels: a Novel and Efficient Method," *Circulation* 86 (Suppl. I):1-227 (1992).

Mulligan et al., "The Basic Science of Gene Therapy," *Science* 260:926-932 (1993).

Nevins, "E2F: A Link Between the Rb Tumor Suppressor Protein and Viral Oncoproteins," *Science* 258:424-429 (1992).

Ostrowski et al., "Glucocorticoid Regulation of Transcription at an Amplified, Episomal Promoter," *Mol. Cell. Biol.* 3:2045-2057 (1983).

Pagano et al., "Association of cdk2 Kinase with the Transcription Factor E2F During S Phase," *Science* 255:1144-1147 (1992).

Ritzenhaler et al., "Regulation of the $\alpha 1(I)$ Collagen Promoter via a Transforming Growth Factor- β Activation Element," *J. Biol. Chem.* 268:13625-13631 (1993).

Ritzenhale~~r~~ et al., "Transforming-growth-factor- β Activation Elements in the Distal Promoter Regions of the Rat $\alpha 1$ Type I Collagen Gene," *Biochem. J.* 280:157-162 (1991).

Rubin et al., "Atherosclerosis in Mice: Getting to the Heart of a Polygenic Disorder," *Trends in Genetics* 10:199-204 (1994).

Schwartz et al., "Coronary Restenosis: Prospects for Solution and New Perspectives from a Porcine Model," *Mayo Clinic Proceedings* 68:54-62 (1993).

Stein et al., "Antisense Oligonucleotides as Therapeutic Agents--is the Bullet Really Magical?" *Science* 261:1004-12 (1993).

Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," *Cell* 63:601-608 (1990).

Tomita et al., "Direct *In Vivo* Gene Introduction into Rat Kidney," *Biochem. Biophys. Res. Comm.* 186:129-134 (1992).

Tseng et al., "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics," *Cancer Gene Ther.* 1:65-71 (1994).

Uhlmann et al., Chemical Reviews 90:543-584 (1990).

Weintraub et al., "Retinoblastoma Protein Switches the E2F Site from Positive to Negative Element," Nature 358:259-261 (1992).

Wu et al., "Inhibition of in Vitro Transcription by Specific Double-stranded Oligodeoxyribonucleotides," Gene 89:203-209 (1990).

Yee et al., "Promoter Interaction of the E1A-inducible Factor E2F and its Potential Role in the Formation of a Multi-component Complex," The EMBO Journal 6:2061-2068 (1987).

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: July 16, 2001

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
50025.003002 Information Disclosure Statement.wpd



21559
PATENT TRADEMARK OFFICE